Sage Journals: Discover world-class research

Abstract

Hypoglycemia is a frequent and often serious complication of diabetes management. While its acute effects on cognition are well documented, growing evidence suggests that recurrent or severe hypoglycemia exposure may also contribute to long-term cognitive decline and increased risk of dementia in patients with diabetes. In fact, clinical and epidemiological data suggest that repeated hypoglycemic events are associated with lower performance in multiple cognitive domains, especially in pediatric and elderly populations. Moreover, meta-analyses and cohort studies highlight a significant association between severe hypoglycemia and increased risk of dementia while cognitive impairment has been shown to also increase the risk of hypoglycemia. This suggests a potential bidirectional relationship between hypoglycemia and cognitive decline. On the molecular level, both animal and human studies reveal that recurrent hypoglycemia induces oxidative stress, impairs mitochondrial dynamics, and leads to synaptic injury, particularly in vulnerable brain regions such as the hippocampus and cortex. These findings underscore the need for personalized glucose management strategies that minimize hypoglycemia risk while maintaining glycemic targets, particularly in populations vulnerable to cognitive impairment. This review summarizes the current understanding of the impact of hypoglycemia on brain function, including its structural, cellular, metabolic, and cognitive consequences.

Keywords

Recurrent hypoglycemia severe hypoglycemia learning memory mild cognitive impairment

Introduction

Cognition is defined by the American Psychological Association as “all forms of knowing and awareness, such as perceiving, conceiving, remembering, reasoning, judging, imagining, and problem solving.”¹ It is influenced by numerous modifiable and non-modifiable conditions such as age, education level, drinking, smoking, social activity, and disease conditions, among others.² Any malfunction in the brain or other organ processes particularly those associated with chronic disease can impair cognition. Such conditions include hypertension, heart disease, stroke, obesity, diabetes, and kidney disease.³ Cognitive impairments can be broadly categorized into neurodegenerative and non-neurodegenerative impairments. Alzheimer’s disease, frontotemporal lobar degeneration, and α-synucleinopathies result in a neurodegenerative type of cognitive impairment. Some nutritional deficiencies, exposure to toxins, metabolic disorders, and cerebrovascular diseases result in a non-neurodegenerative type of cognitive impairment.⁴ The present review article focuses on the impact of exposure of patients with diabetes to hypoglycemia on cognitive impairment.

Diabetes

Diabetes is a chronic condition characterized by hyperglycemia due to either insulin deficiency or impaired glucose uptake.⁵ According to the Centers for Disease Control and Prevention ~38 million Americans have diabetes (>11% of the U.S. population).⁶ Three major types of diabetes exist, with type 1 diabetes (T1D) accounts for 5%–10% of cases, type 2 diabetes (T2D) accounts for 90%–95% of cases, and gestational diabetes occurring in pregnant women. T1D occurs due to insulin deficiency, while T2D results from insulin resistance. Complications of diabetes may include microvascular complications such as neuropathy, nephropathy and retinopathy, as well as macrovascular complications such as cardiovascular disease and stroke. These complications can be episodic or progressive.⁵ Sixty-five percent of deaths in people with diabetes are due to cardiovascular disease,⁵ with stroke and ischemic heart disease being the primary causes of morbidity. Retinopathy is the most prevalent microvascular complication and typically develops slowly over time. It is both treatable and preventable with early detection.⁵ Diabetic nephropathy, characterized by persistent proteinuria, may be present at the time of T2D diagnosis but emerges years after T1D onset. It significantly increases the risk of coronary heart disease and stroke, and death from macrovascular disease. Improved glycemic control can reduce the risk of neuropathy.⁵ Peripheral neuropathy and diabetic ketoacidosis are other secondary complications of diabetes.^5,7 Diabetes is also associated with geriatric symptoms such as cognitive impairment, falls, and depression.⁸ Cognitive decline and dementia are considered late-life complications of diabetes.^8,9

Diabetes and hypoglycemia

Diabetes has numerous potential consequences, which are significantly worsened and more dangerous with inefficient treatment.¹⁰ Multiple daily insulin injection therapy with insulin analogs, as well as continuous subcutaneous insulin infusions along with pump therapies, are considered optimal treatment option for effective management of hyperglycemia in T1D.¹¹ Given that there is progressive beta cell dysfunction in T2D, the specific therapy must be individualized. Basal insulin is added as an initial insulin regimen using either intermediate-acting neutral protamine Hagedorn or long-acting insulin, while short-acting insulin added before meals if needed. Trying to regulate glycemic levels through rigorous insulin therapy, however, may lead to hypoglycemia. Continuous glucose monitoring has shown that most patients with treated diabetes experience hypoglycemia.^12
–14 Recurrent exposure to hypoglycemia (RH) leads to severe consequences, such as hindered counterregulatory defense against hypoglycemia, increasing the frequency and severity of future episodes.¹⁵

The American Diabetes Association (ADA) defines hypoglycemia as “all episodes of an abnormally low plasma glucose concentration that leads to patient harm,”¹⁶ while others define hypoglycemia as a temporary state of significantly reduced blood glucose levels. In most individuals, a blood sugar level lower than 70 mg/dL is defined as a hypoglycemic event.¹⁷ Clinically, hypoglycemia is identified by the presence of symptoms caused by a drop in plasma glucose level and the alleviation of symptoms after the blood glucose level is returned to normal.¹⁸ It is the main hindrance in both T1D and T2D in obtaining optimal glycemic control, which the ADA recommends being HbA1c levels <7%.^19,20 Hypoglycemia can be divided into symptomatic and asymptomatic episodes. Asymptomatic hypoglycemia is characterized by blood sugar levels below the alert value of 70 mg/dL without symptoms,²¹ while symptomatic hypoglycemia involves blood sugar levels below the alert value but with typical hypoglycemia symptoms. Hypoglycemia is classified as mild, moderate, and severe based on the extent of drop in blood glucose levels. Mild (level 1) and moderate (level 2) hypoglycemia refers to blood glucose levels of 54–70 or >54 mg/dL, respectively. Severe (level 3) hypoglycemia is characterized by altered mental and/or physical status requiring assistance.^22,23

Hypoglycemia is a common occurrence among patients with diabetes, particularly those who are insulin dependent.^12
–14 It often results from insulin therapies reducing glucose levels excessively, leaving patients in a hypoglycemic state. While insulin treatment is necessary for controlling diabetic hyperglycemia, wrong dosage may lead to dangerously low glucose levels. In response to falling glucose levels, the body typically initiates an autonomic response characterized by symptoms of sweating, palpitations, and shakiness.²⁴ This response also triggers the release of hormones to restore glucose levels. These symptoms serve as early warning signs, prompting patients to take corrective action. However, repeated hypoglycemic events can lead to hypoglycemia unawareness. Hypoglycemia unawareness is defined as the failure to sense a significant fall in glucose below normal levels.

Those with hypoglycemia unawareness may experience delayed or absent physiological responses, which may prevent them from seeking treatment on time. They instead may experience symptoms of neuroglycopenia. Neuroglycopenia is a severe neurological condition accompanied by reduced consciousness, drowsiness, confusion, loss of consciousness, and even coma.^25,26 This cognitive deficit prevents recognition of hypoglycemia, delaying treatment and increasing the risk of acute complications. Studies show that hypoglycemia unawareness affects 25%–40% of T1D patients who have had disease for >15 years.²⁴ Repeated moderate hypoglycemic episodes increase the risk of severe hypoglycemia due to a decreased counter-regulatory response.²⁶

Metabolic effects of hypoglycemia exposure

Hypoglycemia significantly impacts brain metabolism, as the brain relies almost exclusively on glucose for energy.²⁷ In response to hypoglycemia, the brain adapts by upregulating glucose transporters like GLUT1 and GLUT3 to enhance glucose uptake.²⁷ It also shifts substrate use by promoting uptake and oxidation of amino acids and increasing lactate uptake.²⁷ However, acute or prolonged hypoglycemia can impair glycolysis, reduce key glycolytic intermediates, and alter the TCA cycle activity.²⁷ Earlier, we reported that exposure to mild/moderate RH induces changes in the hippocampal metabolomic profile of insulin-treated rats with streptozotocin-induced diabetes (Figure 1).²⁸

Figure 1.

A diagram summarizing potential mechanisms by which recurrent hypoglycemia impairs cognitive function and increases the risk of dementia in diabetes. Recurrent exposure to hypoglycemia may impair cognitive functions through a combination of metabolic alterations and neuropathological changes in brain. Proposed metabolic effects include upregulation of glucose transporters 1 and 3 to enhance glucose uptake, increased utilization and oxidation of amino acids, and enhanced lactate uptake. Additional hypoglycemia-induced metabolic disturbances include impaired glycolysis, reduced levels of key glycolytic intermediates, altered tricarboxylic cycle activity, changes in the hippocampal metabolomic profile, and mitochondrial dysfunction leading to reduced ATP production and increased oxidative stress due to elevated free radical generation. Neuropathological changes associated with recurrent hypoglycemia include reduced cortical volume (frontal, parietal, and temporal lobes), synaptic loss in hippocampal regions, and blood–brain barrier dysfunction, brain edema, pericyte loss, astrocyte overactivation, and histopathological changes within the hippocampus. Changes encircled with green dotted lines indicate potentially recoverable changes, whereas those encircled with red dotted lines indicate potentially non-recoverable changes. Created in BioRender. https://BioRender.com/icish63

Beyond glucose metabolism, hypoglycemia-associated substrate limitation reduces ATP production, affects mitochondrial function and increases oxidative stress due to elevated free radical formation.^27,29 An earlier study reported lower mitochondrial membrane potential, increased levels of oxidative damage, imbalance of mitochondrial dynamics, and increased mitophagy in the hippocampus of RH-exposed streptozotocin (STZ)-diabetic mice when compared to STZ-diabetic mice.³⁰ Similarly, another study observed that the exposure of cultured astrocytes to recurrent low glucose resulted in mitochondrial dysfunction and increased accumulation of mitochondrial reactive oxygen species.³¹ This dysfunction, particularly in vulnerable brain regions like the hippocampus, may contribute to cognitive impairment. However, inhibition of PARP-1 and pyruvate treatment was found to reduce the extent of acute severe hypoglycemia exposure induced cognitive impairment and neuronal cell death in the CA1 region of the hippocampus (Figure 1).^32,33 Therefore, literature collectively indicates that hypoglycemia impairs mitochondrial function and elevates oxidative stress, contributing to neuronal damage.

The actual physiological effects of hypoglycemia on the brain remain incompletely understood. Chabriat et al. used PET scans to analyze brain metabolism after recurrent insulin-induced severe hypoglycemic episodes in 15 insulin-dependent patients with T1D.²⁵ They found no significant differences in brain metabolism between those with frequent comas and those without, suggesting that brief insulin-induced comas may not cause lasting brain damage. In people with diabetes mellitus, hypoglycemia results in decreased brain glucose levels regardless of hypoglycemia awareness. However, the rate of glucose metabolism was higher in the moderate hypoglycemia-aware group when compared to the moderate hypoglycemia-unaware group.³⁴ Another study demonstrated that the global brain glucose uptake was 20% lower during both moderate hypoglycemia and euglycemia in the moderate hypoglycemia-unaware patients when compared to the hypoglycemia-aware patients.³⁵ This observation is contrary to the expected increased glucose uptake due to elevated levels of glucose transporters in the brain following exposure to moderate hypoglycemia.^36,37 Collectively, these findings underscore that while the brain adapts to short-term glucose deprivation, repeated or severe hypoglycemia can disrupt cellular metabolism, leading to potential long-term neurological effects such as cognitive impairment. The potential metabolic mechanisms causing RH-induced cognitive impairment are shown in Figure 1.

Overall, the literature suggests that RH may drive cognitive impairment through multiple mechanisms acting in synergy, including metabolic, oxidative, and inflammatory changes in the brain (Tables 1 and 2).³⁸ Based on the available evidence, we propose a model in which hypoglycemia-induced substrate limitation leads to increased mitochondrial reactive oxygen species production and impaired mitochondrial function, including reduced ATP production efficiency and further amplification of oxidative stress.²⁹ These early events may subsequently activate additional metabolic and inflammatory pathways during the sub-acute to chronic phases post-hypoglycemia exposure. The cumulative effects of these processes may preferentially affect vulnerable brain regions, such as hippocampus, leading to sustained structural and functional deficits.³⁹ However, the mechanisms underlying the disproportionate susceptibility of the hippocampus to hypoglycemia-induced damage remain unknown.

Table 1.

Summary of cohort and meta-analysis studies on the relationship between hypoglycemia exposure and dementia in diabetes.

Study type	Population	Risk of dementia vs controls	References
Meta-analysis	DM	HR 1.44	Huang et al.⁸⁵
Meta-analysis	T2D	49% ↑ risk of all-cause dementia 31% ↑ risk of Alzheimer’s disease	Tabesh et al.⁸⁶
Prospective population-based study	DM	HR 2.1	Yaffe et al.⁹²
Retrospective population-based study	T2D	1 episode: HR 1.54 ⩾2 episodes: HR 1.80	Han et al.⁹⁵
Longitudinal cohort study	T2D	1 episode: HR 1.26 2 episodes: HR 1.80 3 or more episodes: HR 1.94	Whitmer et al.⁹³
Retrospective population-based study	T2D	All-cause dementia: HR 1.254 Alzheimer’s disease: HR 1.264 Vascular dementia: HR 1.286	Kim et al.⁹⁴
Longitudinal cohort study	T2D	HR 1.30	Zheng et al.⁹⁶
Prospective population-based study	DM	HR 2.1	Yaffe et al.⁹²
Prospective observational study	T2D	HR 2.689	Chin et al.⁹⁸
Population study	T2D	Age-adjusted RR 2.76 Gender-adjusted RR 1.6	Lin and Sheu⁹⁹
Longitudinal cohort study	T1D	HR 1.66	Whitmer et al.¹⁰⁰
Retrospective cohort study	T2D	↑ Risk of dementia indirectly through severe hypoglycemia	Alkabbani et al.¹⁰¹
Retrospective population-based study	T2D	HR 1.83	Alkabbani et al.¹⁰²
Claim data-based cohort study	T2D	22%–25% ↑ risk of dementia	Li et al.¹⁰³
Cohort study	T2D	RR of 2.76	Lin and Sheu⁹⁹

DM: diabetes mellitus; T1D: type 1 diabetes; T2D: type 2 diabetes; HR: hazard ratio; RR: rate ratio.

Table 2.

Overview of how hypoglycemia may contribute to cognitive dysfunction in type 1 diabetes.

Effect category	Temporal classification	Animal/human	Observed effects	References
Structural	Acute	Animal	BBB disruption	Lin et al.⁵¹
	Acute	Animal	Pericyte loss	Lin et al.⁵¹
	Chronic	Human	Structural alterations across brain regions	Kirchhoff et al.,⁴² Aye et al.,⁴³ Ho et al.,⁴⁴ Franc et al.,⁴⁵ and Musen et al.⁴⁷
	Chronic	Human	Cortical atrophy	Perros et al.⁴¹
Functional	Acute	Animal	Increase in amino acid uptake and oxidation	Cardoso et al.¹⁰⁹
		Human	Lactate uptake	De Feyter et al.¹¹⁰
		Animal	Impaired glycolysis	Telushkin et al.¹¹¹
		Animal	Changes in metabolic profile in hippocampus	Dewan et al.²⁸
		Animal	Mitochondrial dysfunction	Cardoso et al.¹¹²
		Animal	Oxidative stress	Cardoso et al.¹¹²
		Animal	Synaptic injury	Zhou et al.³⁰
		Animal	Astrocyte activation	Gao et al.³¹
	Chronic	Animal	GLUT1/GLUT3 upregulation	Simpson et al.¹¹³

BBB: blood–brain barrier; TCA: tricarboxylic acid; GLUT: glucose transporters.

Cellular and structural vulnerability of the brain to hypoglycemia

Due to its high energy requirements and limited glucose storage capacity, the brain is particularly vulnerable to hypoglycemic stress. This section explores how acute and RH affect brain cells, disrupt synaptic function, impair mitochondrial dynamics, and lead to structural changes in various brain regions (Table 2).

Limited information exists on how hypoglycemia affects brain structure. A retrospective MRI study comparing T1D subjects with normal and impaired awareness of hypoglycemia, and non-diabetic controls observed that those with impaired awareness had a smaller volume of the whole cortex (frontal lobe, parietal lobe, and temporal lobe) compared to patients with normal awareness of hypoglycemia, while no significant differences were observed between patients with normal awareness and control. The results of this study suggest that the observed changes may be due to long-term exposure to RH.⁴⁰ Similarly, Perros et al. observed an association between the history of severe hypoglycemia exposure and cortical atrophy in patients with T1D,⁴¹ while a case report also linked a reduced volume of gray matter in the hippocampus with memory impairment in a patient with T1D exposed to recurrent severe hypoglycemia.⁴² Early-onset T1D is associated with increased structural abnormalities in the brain.^43,44 Patients with diabetes display cognitive deficits potentially related to both a decrease in the white matter volume and reduction in gray matter density.^45
–48 Two studies specifically found reduced white matter in patients diagnosed with T1DM, correlating this loss with cognitive decline (Figure 1).^46,48

At the cellular level, hypoglycemia affects different brain regions unevenly. A review article proposes that not all areas of the brain are equally affected by hypoglycemia.⁴⁹ The hippocampal area, temporal area, cerebral cortex, substantia nigra, and basal ganglia area of the brain appear more sensitive to hypoglycemic injury. In studies with normal and STZ-diabetic rats, moderate RH (1–2 mM for 1 h over 5 days) caused sparse neuronal death in the cortex without detectable neuronal death in the hippocampus.⁵⁰ The exposure of RH to STZ-diabetic mice resulted in disorganized pyramidal cells with smaller cell bodies and shrunken or absent nuclei. The morphological condition of the pyramidal cell layer appeared worse in the RH-exposed STZ-diabetic group when compared to the STZ-diabetic group.³⁰ Severe hypoglycemia (<2 mM for 90 min) in STZ-diabetic mice results in blood–brain barrier (BBB) damage, reduced expression of markers of the BBB, brain edema, pericyte loss, and histopathological changes in the hippocampus.⁵¹ Exposure of STZ-diabetic mice to RH results in excessive activation of astrocytes in the cortex, and lower levels of neurotrophins (BDNF/GDNF) and downregulation of related signaling (Figure 1).³¹ The same study observed that the exposure of cultured astrocytes to recurrent low glucose resulted in increased accumulation of mitochondrial reactive oxygen species and mitochondrial dysfunction.

At the subcellular level, the exposure of RH to STZ-diabetic mice results in injury to hippocampal synapses.³⁰ Electron microscopy ultrastructural studies revealed irregular synapses with fewer synaptic vesicles, smaller postsynaptic regions and densities, widened synaptic cleft, and swollen synaptic membrane in RH-exposed STZ-diabetic mice when compared to normal control and STZ-diabetic mice. These subtle changes in synaptic organization likely impair synaptic transmission, membrane excitability, and synaptic plasticity. The study also found an absence of many cristae within mitochondria and a lower numeric density and specific surface area of mitochondria, suggesting significantly swollen mitochondria and a lower number of mitochondria in RH-exposed STZ-diabetic mice when compared to normal control mice. Additionally reported lower mitochondrial membrane potential, increased levels of oxidative damage, imbalance of mitochondrial dynamics, and increased mitophagy in the hippocampus was also found in RH-exposed STZ-diabetic mice when compared to STZ-diabetic mice.³⁰ Another study observed oxidative injury in the hippocampal dendritic area in both normal and STZ-diabetic rats exposed to moderate RH (1–2 mM for 1 h, for 5 consecutive days).⁵⁰ The exposure of differentiated N2a neuroblastoma cells to glucose/pyruvate deprivation resulted in increased tau phosphorylation (Ser262 and Ser396).⁵² Starvation of mice also results in tau hyperphosphorylation.⁵³

The literature demonstrates that hypoglycemia exerts profound effects on the brain at multiple levels, from structural alterations in vulnerable regions to subcellular impairments in synaptic and mitochondrial function as summarized in Figure 1.

Effect of hypoglycemia exposure on cognitive function

Research shows a strong association between cognitive impairment and diabetes with many diabetic individuals exhibiting decreased cognitive functioning and physiological changes within the brain (Table 1).⁵⁴ This is observed in both T1D and T2D patients. Severe hypoglycemia is increasingly recognized as a contributor to cognitive decline in diabetes.⁵⁵ Effects of hypoglycemia can be temporary or long-term. Immediately following a hypoglycemic event, diabetic patients often experience signs of cognitive deficits including irrational behavior, confusion, poor vision, and balance, etc. While these effects are temporary, there are also possible long-term irreversible cognitive effects of hypoglycemia that have been investigated.

Studies offer mixed evidence on the long-term cognitive implications of hypoglycemia. Refuting this theory, the DCCT/EDIC study followed 1441 T1D patients for 6–18 years to assess whether hypoglycemic episodes from intensive insulin therapy caused lasting cognitive decline. Results showed no significant link between hypoglycemic events and cognitive decline. The study concluded that despite an increased risk of severe hypoglycemia, intensive insulin treatment did not have harmful long-term effects on cognitive function. Despite a higher number of severe hypoglycemic events during the DCCT phase in the intensive group (653 vs 205 in the conventional group), the follow-up EDIC phase recorded similar event numbers in both groups (243 vs 254), possibly masking long-term effects of higher number of hypoglycemic comas or seizures observed in intensive treatment group when compared to the conventional treatment group during the DCCT phase of the study.⁵⁶ Another small study of adult T1D patients with retinopathy found no differences in cognitive ability between those with and without a history of recurrent severe hypoglycemia. However, the sample size was too small to draw firm conclusions.⁵⁷ Similarly, adult-onset T1D patients with and without hypoglycemic comas showed no differences in Mini-Mental State Exam scores or P300 latencies, suggesting no lasting impairment.⁵⁸ A study evaluating the long-term effect of recurrent severe hypoglycemia in adult T1D patients found that prior RH exposure does not have any effect on cognitive function. However, an interaction between RH exposure and neuropathy was found to exaggerate the extent of some neurobehavioral dysfunction.⁵⁹

In contrast, other studies highlight factors such as age, frequency, and severity of hypoglycemic events as key determinants of long-term cognitive effects. The Edinburgh Type 2 Diabetes Study reported a link between increased cognitive decline, both in the history of hypoglycemia and incident hypoglycemia during the follow-up period.⁵⁵ In contrast, data from the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial did not observe a significant link between severe hypoglycemia exposure and incident cognitive impairment. Also, the study reported a non-significant inverse relationship between non-severe hypoglycemia and incident cognitive impairment.⁶⁰

In a review article, Firer explains age as a determining factor in how severe the cognitive decline will be following hypoglycemia exposure. Children with hypoglycemic occurrences at a young age are likely to show significant cognitive decline later in life. Children with hypoglycemic occurrences at a young age also showed decreased IQ and cognitive performance later in life.⁶¹ Another study by Hannonen et al. found similar results.⁶² The study included 11 children with a history of T1D and recurrent severe hypoglycemia, 10 children with T1D without a hypoglycemic history, and 10 healthy children as controls. They found that the children with a history of severe hypoglycemia had more neurophysiological deficits and learning impairments and were more likely to need special-education measures.⁶² A 7-year prospective study in pediatric T1D patients found that exposure to hypoglycemic seizures was associated with deficits in perceptual, motor, memory, and attention tasks.⁶³ Similar findings were reported in another pediatric study comparing intensive and conventional diabetes therapies. Children receiving intensive therapy experienced more severe hypoglycemia and showed selective impairments in spatial declarative memory and pattern recognition, potentially linked to temporal lobe dysfunction.⁶⁴ A meta-analysis of pediatric T1D studies further confirmed that recurrent severe hypoglycemia was associated with lower performance in domains such as intelligence, memory, learning, verbal fluency, and language.⁶⁵ In neonates with hypoxic-ischemic encephalopathy treated with therapeutic hypothermia, RH, particularly glucose levels below 2.6 mmol/L, was associated with poorer outcomes in cognitive, language, and socioemotional development, and a significantly higher risk of death or long-term disability.⁶⁶

Studies in adult T1D patients found that those with impaired hypoglycemia awareness and a history of coma had slower psychomotor speed, suggesting lasting cognitive consequences.⁶⁷ The acute severe hypoglycemia exposure in both normal and diabetic subjects causes cognitive impairment in terms of verbal fluency, reaction time, and verbal and visual memory.^68
–70 Lincoln et al. also reported a significant correlation between frequent major hypoglycemic episodes and declines in intelligence in T1D patients.⁷¹ Acute severe hypoglycemia has been shown to transiently impair cognitive function, with recovery taking up to 1.5 days post-episode.^72,73 A meta-analysis of elderly diabetes patients (T1D and T2D) found worse general intelligence scores in those exposed to severe hypoglycemia, with T2D patients also performing worse on memory and psychomotor tests.⁷⁴ Another meta-analysis found that patients with recurrent severe hypoglycemia showed impaired memory in both T1D and T2D populations, with T2D patients also experiencing slower processing speed. However, no significant differences were noted in executive function or general intelligence between groups.⁷⁵

Interestingly, some studies suggest that prior exposure to moderate RH might protect the brain from later severe hypoglycemia. For example, Puente et al. found that moderate RH preconditioning reduced neuronal injury and cognitive decline after severe hypoglycemia.⁷⁶ However, conflicting evidence from another group showed that similar preconditioning worsened outcomes, increasing neuronal death and memory deficits.⁷⁷ Additional studies in non-diabetic rats reported that RH exposure enhanced hippocampal-dependent learning,^78
–80 though the same group later found that RH improved spatial learning but impaired set-shifting ability, potentially due to reduced medial prefrontal cortex glucose metabolism.⁸¹

Several studies by multiple groups of investigators demonstrated deleterious effects of both severe and non-severe hypoglycemia exposure on cognitive function. Moderate RH in STZ-diabetic rats led to oxidative damage in the hippocampus and cortex as well as cognitive deficits.⁵⁰ Our lab similarly found that moderate RH impaired spatial learning and memory in STZ-diabetic rats.⁸² Other studies demonstrated that severe hypoglycemia exposure to STZ-diabetic mice and non-diabetic rats also causes changes in hippocampal histopathology and cognitive impairment.^51,83 RH-induced cognitive decline is linked to astrocyte overactivation, reduced levels of neurotrophins, increased mitochondrial reactive oxygen species, and mitochondrial dysfunction.^30,31

The effect of hypoglycemia on cognition is complex and can depend on numerous factors. The cognitive deficits seen in one patient may vary from those seen in another patient. This can be due to factors such as frequency of hypoglycemic events, severity of hypoglycemic events, age, type of diabetes, etc. Therefore, using clinical studies, it can be difficult to make broad generalizations about the effects of hypoglycemia on cognitive decline. However, well-controlled animal model studies demonstrate that despite all of these external factors, hypoglycemia is linked to cognitive deficits, both short-term and long-term. A study in T2D subjects reported decreased serum levels of neuroproteins like epiregulin (EREG), abhydrolase domain contain 14B, and inositol monophosphate 1, along with increased levels of cysteine-rich intestinal protein 2 (CRIP2) in subjects with mild cognitive impairment (MCI). Moreover, the combined assessment of EREG and CRIP2 was found to moderately differentiate patients with MCI.⁸⁴ However, future studies are required to establish the predictive value of these biomarkers in identifying the relationship between hypoglycemia exposure and cognitive impairment in diabetes.

Exposure to hypoglycemia and risk of dementia

Diabetes is a known risk factor for dementia, but the role of hypoglycemia in this association remains unclear. Huang et al. conducted a systematic review and meta-analysis of over 1.4 million diabetic patients from 10 studies, finding a 44% increased risk of dementia in those with severe hypoglycemic episodes compared to those without.⁸⁵ Notably, this analysis focused solely on dementia, excluding individuals with mild cognitive impairment.⁸⁵ Another meta-analysis of 40 studies representing over seven million patients with diabetes also found that hypoglycemia exposure was linked to increased risk of all-cause dementia (49%) and Alzheimer’s disease (31%).⁸⁶ Consistent with these findings, an earlier review article also summarized multiple studies linking hypoglycemia and increased risk of cognitive decline and dementia in patients with T2D.⁴⁹ The ADVANCE and ACCORD trials further supported this association, demonstrating that impaired cognitive function was both a consequence and a predictor of severe hypoglycemia, suggesting a bidirectional relationship where hypoglycemia contributes to cognitive decline, which in turn impairs diabetes self-management and increases the risk of further hypoglycemic episodes.^87
–92

Additional evidence indicates that severe hypoglycemia may accelerate cognitive deterioration and contribute to the development of dementia, particularly in older adults.⁹ A retrospective study found that exposure to one, two, or three or more severe hypoglycemic episodes was associated with progressively higher risks of dementia by 26%, 80%, and 94% compared to patients with no history of hypoglycemia, respectively.⁹³ This dose-dependent relationships were observed in South Korean T2D patients.⁹⁴ A cohort study in T2D patients reported that exposure to a single episode of severe hypoglycemia causes a 54% higher risk of developing dementia (hazard ratio (HR) = 1.54). This risk further increases to 80% with exposure to two or more episodes of hypoglycemia (HR = 1.80).⁹⁵ This dose-dependence was observed for Alzheimer’s disease but not vascular dementia.⁹⁵ It is plausible that higher number of hypoglycemia exposures are needed to increase the risk of Alzheimer’s disease further. While mechanisms of vascular dementia can be activated by lower number of hypoglycemia exposures and the risk plateaus without further increase by exposures to higher number of hypoglycemia exposures. Future studies are required to clarify the differential effects of hypoglycemia on these dementia subtypes.

After adjusting for multiple covariates, another cohort study in T2D patients also observed an association between the exposure to hypoglycemia and risk of dementia (HR = 1.30).⁹⁶ A retrospective propensity-score matched cohort study using the IQVIA Medical Research Data database showed that diabetic patients with a dementia diagnosis have a significantly higher risk for hypoglycemia exposure.⁹⁷ Another prospective study evaluating the potential association between exposure to hypoglycemia and dementia in older adults with diabetes observed two-fold higher risk of dementia in those who experienced hypoglycemia versus those who did not.⁹² The study also reported that older adult diabetes patients with dementia had a significantly greater risk of experiencing a subsequent hypoglycemic event (HR = 3.1).⁹² A study in older adults with diabetes reported that lower cognitive ability was associated with a two-fold increased risk of severe hypoglycemia over a 4-year follow-up period.⁵⁵ However, the mechanism by which impaired cognitive ability increases the risk of hypoglycemia is unknown and represent an important area for future investigation. A prospective observational study using the Korea National Diabetes Program also linked hypoglycemic episodes to increased dementia risk (HR = 2.689).⁹⁸ A Taiwanese study also reported increased crude rate ratios (RR) for dementia (age-adjusted RR = 2.76 and gender-adjusted RR = 1.6) in diabetic subjects with hypoglycemia compared to those without hypoglycemia.⁹⁹ A longitudinal cohort study that followed 2821 T1D patients also reported 66% higher risk of dementia in those who experienced severe hypoglycemic events when compared to those without (HR = 1.66).¹⁰⁰

A mediation analysis study that examined whether the relationship between insulin use and dementia risk is direct (independent of hypoglycemia) or indirect (mediated through hypoglycemia), observed that the insulin use is associated with dementia through the mediating effect of severe hypoglycemia.¹⁰¹ Similarly, a population-based cohort study using exposure density sampling also reported significantly increased risk of dementia in T2D patients who experienced severe hypoglycemia (HR = 1.83).¹⁰² Compared to late manifestation of severe hypoglycemia early manifestation of severe hypoglycemia contributes more to the risk of dementia in T2D patients.¹⁰³ Supporting these findings, an animal study using streptozotocin-induced diabetic APP/PS1 mice demonstrated that exposure to moderate hypoglycemia led to faster cognitive deterioration in this model of Alzheimer’s disease.¹⁰⁴ Overall, a growing body of clinical and experimental evidence strongly links hypoglycemia to increased risk of cognitive decline and dementia in diabetes. Table 1 summarizes key cohort and meta-analysis studies on this relationship.

Neuroinflammation and associated neurodegenerative processes are key mechanisms contributing to compromised BBB permeability in Alzheimer’s disease and other dementia subtypes.^105,106 Consistent with this, pharmacological modulation that improved BBB integrity also alleviated cognitive dysfunction in a mouse model of sepsis-associated encephalopathy.¹⁰⁷ In addition, inhibition of β amyloid aggregation and associated inflammatory response exerts a beneficial effect on cognitive deficits in APP/PS1 mice.¹⁰⁸ Therefore, these findings suggest that neuroinflammation, BBB dysfunction, and protein aggregation are linked to cognitive impairment. However, whether these mechanisms contribute to RH-associated cognitive impairment in diabetes remains to be determined.

Conclusion

The current body of evidence points to hypoglycemia as a critical factor causing cognitive decline in people with diabetes. While acute episodes can cause transient cognitive deficits, recurrent and severe hypoglycemia may lead to structural brain changes, synaptic damage, mitochondrial dysfunction, and long-term cognitive decline. These effects appear to be particularly pronounced in children, older adults, and patients with impaired awareness of hypoglycemia. Importantly, the relationship between hypoglycemia and cognitive dysfunction is likely bidirectional. Cognitive impairment can reduce a patient’s ability to effectively treat diabetic hyperglycemia, thereby increasing the risk of hypoglycemic episodes (Figure 1). Emerging data link hypoglycemia exposure to a significantly increased risk of developing dementia, especially in individuals with T2D. Despite some inconsistencies in literature, the overall trend supports a detrimental effect of hypoglycemia on brain health. Moving forward, greater emphasis must be placed on preventing hypoglycemia through individualized treatment regimens, the use of continuous glucose monitoring, and patient education. Future studies should aim to identify specific mechanisms underlying hypoglycemia-induced brain dysfunction.

Footnotes

Acknowledgements

We thank Dr. Brant Watson for the critical reading of this manuscript. Ms. Irina Djuraskovic contributed to the initial drafting of the manuscript. The figure was created Created in BioRender. .

Funding

The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the National Institutes of Health grant NS122808 and the Evelyn F McKnight Brain Institute, University of Miami. SM received funds from American Heart Association 24POST1198296. The funding organizations had no role in the design of the study, data collection, analysis, interpretation of results, writing of the manuscript, or the decision to publish the article.

Declaration of conflicting interests

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

ORCID iD

Kunjan R Dave

References

American Psychological Association. Cognition. https://dictionary.apa.org/cognition (2025, accessed 16 October 2025).

Kim

Park

JM.

Factors affecting cognitive function according to gender in community-dwelling elderly individuals. Epidemiol Health 2017; 39: e2017054.

Zuo

The interaction and pathogenesis between cognitive impairment and common cardiovascular diseases in the elderly. Ther Adv Chronic Dis 2022; 13: 20406223211063020.

Gale

Acar

Daffner

KR.

Dementia. Am J Med 2018; 131: 1161–1169.

Deshpande

Harris-Hayes

Schootman

Epidemiology of diabetes and diabetes-related complications. Phys Ther 2008; 88: 1254–1264.

CDC. National diabetes statistics report. https://www.cdc.gov/diabetes/php/data-research/index.html#:~:text=Fast%20Facts%20on%20Diabetes%20*%20Total:%2038.4,(22.8%25%20of%20adults%20with%20diabetes%20are%20undiagnosed (2025, accessed 16 October 2025).

Lowie

Bond

MC.

Diabetic ketoacidosis. Emerg Med Clin North Am 2023; 41: 677–686.

Volpato

Maraldi

Diabetes and disability, cognitive decline, and aging-related outcomes. In: Venkat Narayan

Williams

Gregg

, et al. (eds.) Diabetes public health: from data to policy. New York, NY: Oxford University Press, 2010, pp.225–246.

Bordier

Doucet

Boudet

, et al. Update on cognitive decline and dementia in elderly patients with diabetes. Diabetes Metab 2014; 40: 331–337.

10.

Poonoosamy

Lopes

Huret

, et al. Impact of intensive glycemic treatment on diabetes complications—a systematic review. Pharmaceutics 2023; 15: 1791.

11.

Janez

Guja

Mitrakou

, et al. Insulin therapy in adults with type 1 diabetes mellitus: a narrative review. Diabetes Ther 2020; 11: 387–409.

12.

Gehlaut

Dogbey

Schwartz

, et al. Hypoglycemia in type 2 diabetes—more common than you think: a continuous glucose monitoring study. J Diabetes Sci Technol 2015; 9: 999–1005.

13.

Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group; Tamborlane

Beck

, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464–1476.

14.

Silbert

Salcido-Montenegro

Rodriguez-Gutierrez

, et al. Hypoglycemia among patients with type 2 diabetes: epidemiology, risk factors, and prevention strategies. Curr Diab Rep 2018; 18: 53.

15.

Dagogo-Jack

Craft

Cryer

PE.

Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia. J Clin Invest 1993; 91: 819–828.

16.

Workgroup on Hypoglycemia and American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care 2005; 28: 1245–1249.

17.

Mayo Clinic. Hypoglycemia. https://www.mayoclinic.org/diseases-conditions/hypoglycemia/symptoms-causes/syc-20373685 (2025, accessed 16 October 2025).

18.

Gumprecht

Nabrdalik

Hypoglycemia in patients with insulin‑treated diabetes. Pol Arch Med Wewn 2016; 126: 870–878.

19.

American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes—2024. Diabetes Care 2024; 47: S111–S125.

20.

Cryer

PE.

Hypoglycemia is the limiting factor in the management of diabetes. Diabetes Metab Res Rev 1999; 15: 42–46.

21.

Davis

Spanakis

Cryer

, et al. Hypoglycemia during therapy of diabetes. In: Feingold

Ahmed

Anawalt

, et al. (eds.) Endotext. South Dartmouth, MA: MDText.com, Inc., 2000.

22.

Agiostratidou

Anhalt

Ball

, et al. Standardizing clinically meaningful outcome measures beyond HbA(1c) for type 1 diabetes: a consensus report of the American Association of Clinical Endocrinologists, the American Association of Diabetes Educators, the American Diabetes Association, the Endocrine Society, JDRF International, The Leona M. and Harry B. Helmsley Charitable Trust, the Pediatric Endocrine Society, and the T1D Exchange. Diabetes Care 2017; 40: 1622–1630.

23.

McCall

Lieb

Gianchandani

, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2023; 108: 529–562.

24.

Cheah

Amiel

SA.

Metabolic neuroimaging of the brain in diabetes mellitus and hypoglycaemia. Nat Rev Endocrinol 2012; 8: 588–597.

25.

Chabriat

Sachon

Levasseur

, et al. Brain metabolism after recurrent insulin induced hypoglycaemic episodes: a PET study. J Neurol Neurosurg Psychiatry 1994; 57: 1360–1365.

26.

Halimi

Acute consequences of hypoglycaemia in diabetic patients. Diabetes Metab 2010; 36(suppl 3): S75–S83.

27.

Rehni

Dave

KR.

Impact of hypoglycemia on brain metabolism during diabetes. Mol Neurobiol 2018; 55: 9075–9088.

28.

Dewan

Shukla

Rehni

, et al. Exposure to recurrent hypoglycemia alters hippocampal metabolism in treated streptozotocin-induced diabetic rats. CNS Neurosci Ther 2020; 26: 126–135.

29.

Dave

Tamariz

Desai

, et al. Recurrent hypoglycemia exacerbates cerebral ischemic damage in streptozotocin-induced diabetic rats. Stroke 2011; 42: 1404–1411.

30.

Zhou

Huang

Zheng

, et al. Recurrent nonsevere hypoglycemia exacerbates imbalance of mitochondrial homeostasis leading to synapse injury and cognitive deficit in diabetes. Am J Physiol Endocrinol Metab 2018; 315: E973–E986.

31.

Gao

Ren

Zhou

, et al. Recurrent non-severe hypoglycemia aggravates cognitive decline in diabetes and induces mitochondrial dysfunction in cultured astrocytes. Mol Cell Endocrinol 2021; 526: 111192.

32.

Suh

Aoyama

Chen

, et al. Hypoglycemic neuronal death and cognitive impairment are prevented by poly(ADP-ribose) polymerase inhibitors administered after hypoglycemia. J Neurosci 2003; 23: 10681–10690.

33.

Suh

Aoyama

Matsumori

, et al. Pyruvate administered after severe hypoglycemia reduces neuronal death and cognitive impairment. Diabetes 2005; 54: 1452–1458.

34.

Bingham

Dunn

Smith

, et al. Differential changes in brain glucose metabolism during hypoglycaemia accompany loss of hypoglycaemia awareness in men with type 1 diabetes mellitus. An [¹¹C]-3-O-methyl-D-glucose PET study. Diabetologia 2005; 48: 2080–2089.

35.

Cranston

Reed

Marsden

, et al. Changes in regional brain ¹⁸F-fluorodeoxyglucose uptake at hypoglycemia in type 1 diabetic men associated with hypoglycemia unawareness and counter-regulatory failure. Diabetes 2001; 50: 2329–2336.

36.

Kumagai

Kang

Boado

, et al. Upregulation of blood–brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 1995; 44: 1399–1404.

37.

Uehara

Nipper

McCall

AL.

Chronic insulin hypoglycemia induces GLUT-3 protein in rat brain neurons. Am J Physiol 1997; 272: E716–E719.

38.

McNeilly

Gallagher

Dinkova-Kostova

, et al. Nrf2-mediated neuroprotection against recurrent hypoglycemia is insufficient to prevent cognitive impairment in a rodent model of type 1 diabetes. Diabetes 2016; 65: 3151–3160.

39.

Simon

Schmidley

Meldrum

, et al. Excitotoxic mechanisms in hypoglycaemic hippocampal injury. Neuropathol Appl Neurobiol 1986; 12: 567–576.

40.

Bednarik

Moheet

Grohn

, et al. Type 1 diabetes and impaired awareness of hypoglycemia are associated with reduced brain gray matter volumes. Front Neurosci 2017; 11: 529.

41.

Perros

Deary

Sellar

, et al. Brain abnormalities demonstrated by magnetic resonance imaging in adult IDDM patients with and without a history of recurrent severe hypoglycemia. Diabetes Care 1997; 20: 1013–1018.

42.

Kirchhoff

Lugar

Smith

, et al. Hypoglycaemia-induced changes in regional brain volume and memory function. Diabet Med 2013; 30: e151–e156.

43.

Aye

Reiss

Kesler

, et al. The feasibility of detecting neuropsychologic and neuroanatomic effects of type 1 diabetes in young children. Diabetes Care 2011; 34: 1458–1462.

44.

Weller

Ives

, et al. Prevalence of structural central nervous system abnormalities in early-onset type 1 diabetes mellitus. J Pediatr 2008; 153: 385–390.

45.

Franc

Kodl

Mueller

, et al. High connectivity between reduced cortical thickness and disrupted white matter tracts in long-standing type 1 diabetes. Diabetes 2011; 60: 315–319.

46.

Kodl

Franc

Rao

, et al. Diffusion tensor imaging identifies deficits in white matter microstructure in subjects with type 1 diabetes that correlate with reduced neurocognitive function. Diabetes 2008; 57: 3083–3089.

47.

Musen

Lyoo

Sparks

, et al. Effects of type 1 diabetes on gray matter density as measured by voxel-based morphometry. Diabetes 2006; 55: 326–333.

48.

Wessels

Rombouts

Remijnse

, et al. Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. Diabetologia 2007; 50: 1763–1769.

49.

Sheen

Sheu

WH.

Association between hypoglycemia and dementia in patients with type 2 diabetes. Diabetes Res Clin Pract 2016; 116: 279–287.

50.

Won

Yoo

Kauppinen

, et al. Recurrent/moderate hypoglycemia induces hippocampal dendritic injury, microglial activation, and cognitive impairment in diabetic rats. J Neuroinflammation 2012; 9: 182.

51.

Lin

Chen

, et al. Severe hypoglycemia contributing to cognitive dysfunction in diabetic mice is associated with pericyte and blood–brain barrier dysfunction. Front Aging Neurosci 2021; 13: 775244.

52.

Lee

Shih

, et al. Hypoglycemia induces tau hyperphosphorylation. Curr Alzheimer Res 2013; 10: 298–308.

53.

Yanagisawa

Planel

Ishiguro

, et al. Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer’s disease. FEBS Lett 1999; 461: 329–333.

54.

Moheet

Mangia

Seaquist

ER.

Impact of diabetes on cognitive function and brain structure. Ann N Y Acad Sci 2015; 1353: 60–71.

55.

Feinkohl

Aung

Keller

, et al. Severe hypoglycemia and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes Care 2014; 37: 507–515.

56.

Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study Research Group; Jacobson

Musen

, et al. Long-term effect of diabetes and its treatment on cognitive function. N Engl J Med 2007; 356: 1842–1852.

57.

Ferguson

Blane

Perros

, et al. Cognitive ability and brain structure in type 1 diabetes: relation to microangiopathy and preceding severe hypoglycemia. Diabetes 2003; 52: 149–156.

58.

Kramer

Fasching

Madl

, et al. Previous episodes of hypoglycemic coma are not associated with permanent cognitive brain dysfunction in IDDM patients on intensive insulin treatment. Diabetes 1998; 47: 1909–1914.

59.

Ryan

Williams

Finegold

, et al. Cognitive dysfunction in adults with type 1 (insulin-dependent) diabetes mellitus of long duration: effects of recurrent hypoglycaemia and other chronic complications. Diabetologia 1993; 36: 329–334.

60.

Cukierman-Yaffe

Bosch

Jung

, et al. Hypoglycemia and incident cognitive dysfunction: a post hoc analysis from the ORIGIN trial. Diabetes Care 2019; 42: 142–147.

61.

Frier

BM.

Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications. Nat Rev Endocrinol 2014; 10: 711–722.

62.

Hannonen

Tupola

Ahonen

, et al. Neurocognitive functioning in children with type-1 diabetes with and without episodes of severe hypoglycaemia. Dev Med Child Neurol 2003; 45: 262–268.

63.

Rovet

Ehrlich

RM.

The effect of hypoglycemic seizures on cognitive function in children with diabetes: a 7-year prospective study. J Pediatr 1999; 134: 503–506.

64.

Hershey

Bhargava

Sadler

, et al. Conventional versus intensive diabetes therapy in children with type 1 diabetes: effects on memory and motor speed. Diabetes Care 1999; 22: 1318–1324.

65.

Blasetti

Chiuri

Tocco

, et al. The effect of recurrent severe hypoglycemia on cognitive performance in children with type 1 diabetes: a meta-analysis. J Child Neurol 2011; 26: 1383–1391.

66.

Tan

JKG

Minutillo

McMichael

, et al. Impact of hypoglycaemia on neurodevelopmental outcomes in hypoxic ischaemic encephalopathy: a retrospective cohort study. BMJ Paediatr Open 2017; 1: e000175.

67.

Bortolotti

Zarantonello

Uliana

, et al. Impaired cognitive processing speed in type 1 diabetic patients who had severe/recurrent hypoglycaemia. J Diabetes Complications 2018; 32: 1040–1045.

68.

Amiel

SA.

Cognitive function testing in studies of acute hypoglycaemia: rights and wrongs?. Diabetologia 1998; 41: 713–719.

69.

Maran

Crepaldi

Trupiani

, et al. Brain function rescue effect of lactate following hypoglycaemia is not an adaptation process in both normal and type I diabetic subjects. Diabetologia 2000; 43: 733–741.

70.

Widom

Simonson

DC.

Glycemic control and neuropsychologic function during hypoglycemia in patients with insulin-dependent diabetes mellitus. Ann Intern Med 1990; 112: 904–912.

71.

Lincoln

Faleiro

Kelly

, et al. Effect of long-term glycemic control on cognitive function. Diabetes Care 1996; 19: 656–658.

72.

Evans

Pernet

Lomas

, et al. Delay in onset of awareness of acute hypoglycemia and of restoration of cognitive performance during recovery. Diabetes Care 2000; 23: 893–897.

73.

Strachan

Deary

Ewing

, et al. Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes. Diabetes Care 2000; 23: 305–312.

74.

Sun

Wen

, et al. Effect of hypoglycemia on cognitive performance in older patients with diabetes: a meta-analysis. Ann Endocrinol 2024; 85: 56–62.

75.

Chen

Liu

, et al. Effect of recurrent severe hypoglycemia on cognitive performance in adult patients with diabetes: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2017; 37: 642–648.

76.

Puente

Silverstein

Bree

, et al. Recurrent moderate hypoglycemia ameliorates brain damage and cognitive dysfunction induced by severe hypoglycemia. Diabetes 2010; 59: 1055–1062.

77.

Languren

Montiel

Ramirez-Lugo

, et al. Recurrent moderate hypoglycemia exacerbates oxidative damage and neuronal death leading to cognitive dysfunction after the hypoglycemic coma. J Cereb Blood Flow Metab 2019; 39: 808–821.

78.

McNay

Sherwin

RS.

Effect of recurrent hypoglycemia on spatial cognition and cognitive metabolism in normal and diabetic rats. Diabetes 2004; 53: 418–425.

79.

McNay

Williamson

McCrimmon

, et al. Cognitive and neural hippocampal effects of long-term moderate recurrent hypoglycemia. Diabetes 2006; 55: 1088–1095.

80.

Osborne

O’Leary

Fitzgerald

, et al. Context-dependent memory following recurrent hypoglycaemia in non-diabetic rats is mediated via glucocorticoid signalling in the dorsal hippocampus. Diabetologia 2017; 60: 182–191.

81.

Jahagirdar

Ramcharitar

Cotero

, et al. Moderate recurrent hypoglycemia markedly impairs set-shifting ability in a rodent model: cognitive and neurochemical effects. Open Diabetes J 2012; 5: 1–7.

82.

Shukla

Fuchs

Liu

, et al. Recurrent hypoglycemia exacerbates cerebral ischemic damage in diabetic rats via enhanced post-ischemic mitochondrial dysfunction. Transl Stroke Res 2019; 10: 78–90.

83.

Nikpendar

Javanbakht

Moosavian

, et al. Effect of recurrent severe insulin-induced hypoglycemia on the cognitive function and brain oxidative status in the rats. Diabetol Metab Syndr 2024; 16: 161.

84.

Zhang

Wang

Yang

, et al. Spontaneous brain activity in patients with type 2 diabetes: linking serum neuroproteins to cognitive ability. Diabetol Metab Syndr 2025; 17: 174.

85.

Huang

Zhu

Association between hypoglycemia and dementia in patients with diabetes: a systematic review and meta-analysis of 1.4 million patients. Diabetol Metab Syndr 2022; 14: 31.

86.

Tabesh

Sacre

Mehta

, et al. Associations of glycaemia-related risk factors with dementia and cognitive decline in individuals with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 2025; 42: e70123.

87.

de Galan

Zoungas

Chalmers

, et al. Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia 2009; 52: 2328–2336.

88.

Feil

Rajan

Soroka

, et al. Risk of hypoglycemia in older veterans with dementia and cognitive impairment: implications for practice and policy. J Am Geriatr Soc 2011; 59: 2263–2272.

89.

Prinz

Stingl

Dapp

, et al. High rate of hypoglycemia in 6770 type 2 diabetes patients with comorbid dementia: a multicenter cohort study on 215,932 patients from the German/Austrian diabetes registry. Diabetes Res Clin Pract 2016; 112: 73–81.

90.

Punthakee

Miller

Launer

, et al. Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 2012; 35: 787–793.

91.

Thorpe

Gellad

Good

, et al. Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes Care 2015; 38: 588–595.

92.

Yaffe

Falvey

Hamilton

, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med 2013; 173: 1300–1306.

93.

Whitmer

Karter

Yaffe

, et al. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301: 1565–1572.

94.

Kim

Park

Moon

, et al. Hypoglycemia and dementia risk in older patients with type 2 diabetes mellitus: a propensity-score matched analysis of a population-based cohort study. Diabetes Metab J 2020; 44: 125–133.

95.

Han

Lee

, et al. Severe hypoglycemia increases dementia risk and related mortality: a nationwide, population-based cohort study. J Clin Endocrinol Metab 2022; 107: e1976–e1986.

96.

Zheng

Price

, et al. Glycemic control, diabetic complications, and risk of dementia in patients with diabetes: results from a large U.K. cohort study. Diabetes Care 2021; 44: 1556–1563.

97.

Alsharif

Wong

ICK

, et al. The association between dementia and the risk of hypoglycaemia events among patients with diabetes mellitus: a propensity-score matched cohort analysis. Front Med 2023; 10: 1177636.

98.

Chin

Rhee

Chon

, et al. Hypoglycemia is associated with dementia in elderly patients with type 2 diabetes mellitus: an analysis based on the Korea National Diabetes Program Cohort. Diabetes Res Clin Pract 2016; 122: 54–61.

99.

Lin

Sheu

WH.

Hypoglycaemic episodes and risk of dementia in diabetes mellitus: 7-year follow-up study. J Intern Med 2013; 273: 102–110.

100.

Whitmer

Gilsanz

Quesenberry

, et al. Association of type 1 diabetes and hypoglycemic and hyperglycemic events and risk of dementia. Neurology 2021; 97: e275–e283.

101.

Alkabbani

Maxwell

Marrie

, et al. Insulin, hypoglycaemia and dementia: a causal mediation analysis showcasing challenges and potential opportunities. Diabetes Obes Metab 2024; 26: 1120–1124.

102.

Alkabbani

Maxwell

Marrie

, et al. Hypoglycaemia and the risk of dementia: a population-based cohort study using exposure density sampling. Int J Epidemiol 2023; 52: 908–920.

103.

Kuo

Chang

, et al. Association between trajectory of severe hypoglycemia and dementia in patients with type 2 diabetes: a population-based study. J Epidemiol 2022; 32: 423–430.

104.

Cui

, et al. Recurrent moderate hypoglycemia accelerates the progression of Alzheimer’s disease through impairment of the TRPC6/GLUT3 pathway. JCI Insight 2022; 7.

105.

Kurz

Walker

Rauchmann

, et al. Dysfunction of the blood–brain barrier in Alzheimer’s disease: evidence from human studies. Neuropathol Appl Neurobiol 2022; 48: e12782.

106.

Raz

Knoefel

Bhaskar

The neuropathology and cerebrovascular mechanisms of dementia. J Cereb Blood Flow Metab 2016; 36: 172–186.

107.

Yue

Zeng

, et al. Inhibition of neutrophil extracellular traps alleviates blood–brain barrier disruption and cognitive dysfunction via Wnt3/beta-catenin/TCF4 signaling in sepsis-associated encephalopathy. J Neuroinflammation 2025; 22: 87.

108.

Liu

Ding

Zhao

, et al. Biological effects and mechanism of beta-amyloid aggregation inhibition by penetrable recombinant human HspB5–ACD structural domain protein. Biomed Pharmacother 2024; 175: 116661.

109.

Cardoso

Carvalho

Santos

, et al. Impact of STZ-induced hyperglycemia and insulin-induced hypoglycemia in plasma amino acids and cortical synaptosomal neurotransmitters. Synapse 2011; 65: 457–466.

110.

De Feyter

Mason

Shulman

, et al. Increased brain lactate concentrations without increased lactate oxidation during hypoglycemia in type 1 diabetic individuals. Diabetes 2013; 62: 3075–3080.

111.

Telushkin

Nozdrachev

Potapov

, et al. Glycolysis and oxidation enzyme activity in rat brain during insulin-induced hypoglycemia against the background of alloxan-induced diabetes mellitus. Bull Exp Biol Med 2005; 140: 695–697.

112.

Cardoso

Santos

Correia

, et al. Insulin-induced recurrent hypoglycemia exacerbates diabetic brain mitochondrial dysfunction and oxidative imbalance. Neurobiol Dis 2013; 49: 1–12.

113.

Simpson

Appel

Hokari

, et al. Blood–brain barrier glucose transporter: effects of hypo- and hyperglycemia revisited. J Neurochem 1999; 72: 238–247.

The cognitive consequences of hypoglycemia in diabetes

Abstract

Keywords

Introduction

Diabetes

Diabetes and hypoglycemia

Metabolic effects of hypoglycemia exposure

Cellular and structural vulnerability of the brain to hypoglycemia

Effect of hypoglycemia exposure on cognitive function

Exposure to hypoglycemia and risk of dementia

Conclusion

Footnotes

Acknowledgements

Funding

Declaration of conflicting interests

ORCID iD

References